Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)

AIMS: To evaluate the short‐term cost‐effectiveness of insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100) from a Canadian public healthcare payer perspective in patients with type 2 diabetes (T2D) who are at high risk of cardiovascular events and hypoglycaemia. MATERIALS AN...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollock, Richard F., Heller, Simon, Pieber, Thomas R., Woo, Vincent, Gundgaard, Jens, Hallén, Nino, Luckevich, Maria, Tutkunkardas, Deniz, Zinman, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618053/
https://www.ncbi.nlm.nih.gov/pubmed/30924579
http://dx.doi.org/10.1111/dom.13730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618053/
https://www.ncbi.nlm.nih.gov/pubmed/30924579
http://dx.doi.org/10.1111/dom.13730

Ejemplares similares